Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

EIKN

Eikon Therapeutics Inc

Jun 10 • 04:00PM ET

8.36

-0.41 -4.68 %

Healthcare • Biotechnology • USA • Small • NASD

Peers: IDYA RCUS TNGX CGON NUVL BMRN INCY KYMR RYTM KRYS

| Held by: VTI VXF SCHA SCHB VTWO TMED TINY VTWG BMED VTWV

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	53.18%	Shs Outstand	54.14M	Perf Week	-11.35%
Market Cap	452.61M	Forward P/E	-	EPS next Y	-6.66	Insider Trans	10.94%	Shs Float	25.35M	Perf Month	-15.98%
Enterprise Value	194.86M	PEG	-	EPS next Q	-1.58	Inst Own	38.10%	Short Float	16.04%	Perf Quarter	-36.57%
Income	-	P/S	-	EPS this Y	94.00%	Inst Trans	78.12%	Short Ratio	11.64	Perf Half Y	-
Sales	-	P/B	0.82	EPS next Y	3.62%	ROA	-	Short Interest	4.07M	Perf YTD	-44.27%
Book/sh	10.17	P/C	0.88	EPS next 5Y	63.03%	ROE	-	52W High	17.40 -51.95%	Perf Year	-
Cash/sh	9.47	P/FCF	-	EPS past 3/5Y	-13.35% -	ROIC	-	52W Low	7.90 5.82%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.11% 10.84%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.99	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.75	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	36.33	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	11.75	EPS Q/Q	-	SMA20	-20.36%	Beta	-	Target Price	24.80
Payout	-	Debt/Eq	0.46	Sales Q/Q	-	SMA50	-18.48%	Rel Volume	0.39	Prev Close	8.77
Employees	-	LT Debt/Eq	0.45	Earnings	May 11 AMC	SMA200	-28.00%	Avg Volume	349.25K	Price	8.36
IPO	Feb 05, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	-24.42% -	Trades		Volume	136,248	Change	-4.68%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-02-26	Initiated	Morgan Stanley	Overweight	$32
Mar-02-26	Initiated	Mizuho	Outperform	$26
Mar-02-26	Initiated	JP Morgan	Overweight	$29
Mar-02-26	Initiated	Cantor Fitzgerald	Overweight
Mar-02-26	Initiated	BofA Securities	Buy	$34
Feb-26-26	Initiated	Wedbush	Underperform	$7

Jun-08-26 08:00AM	Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors (GlobeNewswire)
May-30-26 02:30PM	Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology (GlobeNewswire)
May-21-26 05:05PM	Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (GlobeNewswire)
May-11-26 04:01PM	Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates (GlobeNewswire) +15.88%
Mar-30-26 07:48AM	Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates (GlobeNewswire)
09:42AM	Loading…
Feb-26-26 09:42AM	Spotify upgraded, First Solar downgraded: Wall Street's top analyst calls (The Fly) -8.39%
Feb-24-26 12:02PM	Medtronic Diabetes Unit MiniMed Seeks $784 Million in US IPO (Bloomberg)
Feb-09-26 08:30AM	Wall Street Braces For IPO Boom: Goldman Says 2026 Listings Could Hit $160 Billion As Tech, AI Lead (Benzinga)
Feb-06-26 04:18PM	Jennifer Garner's Once Upon a Farm Rises Nearly 20% To Wrap Up Busy Week for IPOs (Barrons.com)
Feb-05-26 07:23PM	This Mobile App Marketing Firm Is Holding Off an IPO for Now (Barrons.com)
Feb-04-26 07:59PM	Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Eikon Therapeutics is a biopharmaceutical company. It engages in the development of medicines for unmet medical needs. The company was founded in 2019 and is headquartered in Millbrae, CA.

Ph.D.Dr. Roger M. Perlmutter M.D.

Chief Operating OfficerMr. Michael A. Klobuchar

M.D.Dr. Roy D. Baynes FACP

Co-Founder & Member of Scientific Advisory BoardDr. Robert Tjian Ph.D.

Co-Founder & Member of Scientific Advisory BoardDr. Eric Betzig Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Column Group IV GP, LP	10% Owner	Feb 06 '26	Buy	18.00	2,117,760	38,119,680	4,312,139	Feb 09 09:19 PM
Foresite Capital Management IV	10% Owner	Feb 04 '26	Buy	18.00	55,555	999,990	1,318,983	Feb 06 07:37 PM
FRAZIER KENNETH C	Director	Feb 04 '26	Buy	18.00	111,111	1,999,998	111,111	Feb 06 06:33 PM
Wolfe Josh	Director	Feb 04 '26	Buy	18.00	277,776	4,999,968	138,888	Feb 06 06:27 PM
Lux Venture Partners V, LLC	10% Owner	Feb 04 '26	Buy	18.00	277,776	4,999,968	138,888	Feb 06 06:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EIKN

Eikon Therapeutics Inc

Upgrade your Finviz experience